Omeros (NASDAQ:OMER) Stock Rating Upgraded by StockNews.com

Omeros (NASDAQ:OMERGet Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Sunday.

Separately, Cantor Fitzgerald lowered Omeros from an “overweight” rating to a “neutral” rating in a research note on Friday, November 10th.

Check Out Our Latest Stock Report on OMER

Omeros Stock Performance

OMER stock opened at $3.92 on Friday. The company has a quick ratio of 2.39, a current ratio of 2.39 and a debt-to-equity ratio of 10.80. The business’s fifty day simple moving average is $3.29 and its two-hundred day simple moving average is $2.89. Omeros has a twelve month low of $0.92 and a twelve month high of $7.80. The firm has a market cap of $246.14 million, a price-to-earnings ratio of 12.23 and a beta of 1.30.

Insider Activity

In other news, CEO Gregory A. Md Demopulos purchased 15,000 shares of the business’s stock in a transaction dated Friday, November 17th. The shares were purchased at an average price of $1.68 per share, for a total transaction of $25,200.00. Following the completion of the purchase, the chief executive officer now owns 123,945 shares in the company, valued at approximately $208,227.60. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders own 10.90% of the company’s stock.

Hedge Funds Weigh In On Omeros

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in Omeros by 258.0% in the second quarter. BlackRock Inc. now owns 4,154,952 shares of the biopharmaceutical company’s stock valued at $22,603,000 after purchasing an additional 2,994,468 shares during the last quarter. Vanguard Group Inc. grew its stake in Omeros by 2.3% in the first quarter. Vanguard Group Inc. now owns 3,434,697 shares of the biopharmaceutical company’s stock valued at $20,642,000 after purchasing an additional 76,869 shares during the last quarter. Stifel Financial Corp grew its stake in Omeros by 4.7% in the second quarter. Stifel Financial Corp now owns 2,056,835 shares of the biopharmaceutical company’s stock valued at $11,189,000 after purchasing an additional 93,215 shares during the last quarter. State Street Corp grew its stake in Omeros by 2.8% in the first quarter. State Street Corp now owns 1,412,609 shares of the biopharmaceutical company’s stock valued at $8,490,000 after purchasing an additional 38,498 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Omeros by 98.4% in the second quarter. Geode Capital Management LLC now owns 1,253,711 shares of the biopharmaceutical company’s stock valued at $6,820,000 after purchasing an additional 621,819 shares during the last quarter. Hedge funds and other institutional investors own 41.70% of the company’s stock.

About Omeros

(Get Free Report)

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

Further Reading

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.